Exhibit
32.2
CERTIFICATION
PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED
PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In
connection with the Quarterly Report of Galectin Therapeutics Inc. (the “Company”)
on Form 10-Q for the period ended June 30, 2025 as filed with the Securities
and Exchange Commission on the date hereof (the “Report”), I, Jack W.
Callicutt, Chief Financial Officer of the Company, certify, pursuant to 18
U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002,
that, to my knowledge:
(1) The Report fully complies with the
requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934;
and
(2) The information contained in the Report
fairly presents, in all material respects, the financial condition and results
of operations of the Company.
| | |
|
Date: August 14, 2025
|
|
/s/ Jack W. Callicutt
|
|
|
Name:
|
Jack W. Callicutt
|
|
|
Title:
|
Chief Financial Officer
|
|
|
|
(principal financial and
accounting officer)
|
A signed original of this written
statement required by Section 906, or other document authenticating,
acknowledging, or otherwise adopting the signature that appears in typed form
within the electronic version of this written statement required by Section
906, has been provided to Galectin Therapeutics Inc. and will be retained by
Galectin Therapeutics Inc. and furnished to the Securities and Exchange Commission
or its staff upon request.